Asensus Surgical
Founded Year
2006Stage
Reverse Merger | IPOTotal Raised
$93.42MMarket Cap
0.06BStock Price
0.24About Asensus Surgical
Asensus Surgical is a company that focuses on the development and manufacturing of digital laparoscopy and surgical robotics. The company's main offerings include the Senhance Surgical System and the Intelligent Surgical Unit, which are designed to enhance surgeon control, reduce surgical variability, and provide real-time insights to improve surgical outcomes. Asensus Surgical primarily serves the healthcare industry, particularly the surgical technology sector. Asensus Surgical was formerly known as TransEnterix. It was founded in 2006 and is based in Morrisville, North Carolina.
Loading...
Asensus Surgical's Product Videos
Asensus Surgical's Products & Differentiators
Senhance Surgical System
The Senhance® Surgical System is the first of its kind and the only digital laparoscopic platform that leverages augmented intelligence to provide unmatched performance and improved patient outcomes through machine learning. The Senhance Surgical System is designed to support hospitals and help surgeons thrive in today’s healthcare landscape. This digital laparoscopic platform removes the economic limitations of current robotic systems with standard reusable instruments and an open-platform architecture strategy that enables hospitals to leverage existing technology investments. That keeps time and cost-per-procedure comparable to traditional laparoscopy, so that the benefits of robotics can reach more patients, in more care settings, for a greater variety of procedures.
Loading...
Asensus Surgical Patents
Asensus Surgical has filed 140 patents.
The 3 most popular patent topics include:
- surgery
- surgical instruments
- surgical robots
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
10/24/2022 | 11/21/2023 | Surgery, Graphical control elements, Surgical robots, Surgical instruments, Surgical procedures and techniques | Grant |
Application Date | 10/24/2022 |
|---|---|
Grant Date | 11/21/2023 |
Title | |
Related Topics | Surgery, Graphical control elements, Surgical robots, Surgical instruments, Surgical procedures and techniques |
Status | Grant |
Latest Asensus Surgical News
Nov 21, 2023
The collaboration will leverage the NVIDIA Holoscan and IGX Orin platforms, which feature ultra-low latency data transfer, superior image processing, and scalability, to enhance image processing, visualisation and AI-based decision-making LTTS, NVIDIA partner for AI architecture for medical devices. (Credit: Amir Shtanger/Wikipedia) US-based technology firm NVIDIA and Indian engineering services company L&T Technology Services (LTTS) have partnered to develop software-defined architectures for medical devices. An architecture is a scalable platform that supports various applications and provides a real-time decision-making tool for the medical fraternity. It will be developed as an advanced solution to address the industry-wide challenges of availability, cost, and dependencies associated with custom and unique hardware components. The collaboration will leverage the NVIDIA Holoscan and IGX Orin platforms, which feature ultra-low latency data transfer, superior image processing, and scalability. It will enable enhanced visualisation for image processing and AI-based decision-making support, such as for polyp detection and classification. NVIDIA enterprise business senior vice president Shanker Trivedi said: “The combination of LTTS’ expertise in medical-device development and NVIDIA’s full-stack edge AI computing platform delivers unprecedented value to the medical technology industry by accelerating the development of AI-enabled, software-defined medical devices. “This collaboration provides a complete solution for customers looking to transition to a software-defined business model via real-time AI applications.” The architecture will feature an image processing pipeline for noise reduction, edge and contrast enhancement, texture and colour enhancement, and speckle correction. It also includes AI/ML models for the detection, identification, and classification of polyps – abnormal growths often found during colonoscopies. The solution comes with a user-friendly interface and facilitates an effortless integration of the image processing pipeline for visualisation. The architecture is expected to provide low-latency data transfer, superior image processing without performance bottlenecks, and scalability. L&T Technology Services CEO and managing director Amit Chadha said: “Our collaboration with NVIDIA helps us push the boundaries of what’s possible in medical imaging. “The combination of the NVIDIA Holoscan software platform for edge AI inference and the NVIDIA IGX Orin hardware platform accelerates the development of AI-powered medical imaging solutions by enhancing image quality and real-time clinical decision-making support, making clinicians more efficient and improving patient outcomes.” Earlier this year, NVIDIA teamed up with Asensus Surgical to advance the development of Asensus’ Intelligent Surgical Unit (ISU) offering. Do you have interesting content to share with us? Enter your email address so we can get in touch. Related Article
Asensus Surgical Frequently Asked Questions (FAQ)
When was Asensus Surgical founded?
Asensus Surgical was founded in 2006.
Where is Asensus Surgical's headquarters?
Asensus Surgical's headquarters is located at 635 Davis Drive, Morrisville.
What is Asensus Surgical's latest funding round?
Asensus Surgical's latest funding round is Reverse Merger.
How much did Asensus Surgical raise?
Asensus Surgical raised a total of $93.42M.
Who are the investors of Asensus Surgical?
Investors of Asensus Surgical include SafeStitch Medical, SV Health Investors, Synergy Life Science Partners, InterSouth Partners, Aisling Capital and 6 more.
Who are Asensus Surgical's competitors?
Competitors of Asensus Surgical include CMR Surgical, Activ Surgical, Vicarious Surgical, Quantum Surgical, Medrobotics and 7 more.
What products does Asensus Surgical offer?
Asensus Surgical's products include Senhance Surgical System.
Who are Asensus Surgical's customers?
Customers of Asensus Surgical include US Hospital.
Loading...
Compare Asensus Surgical to Competitors
CMR Surgical operates as a surgical robotics company developing universal robotic systems for minimal access surgery. It aims to make minimal-access surgery universally accessible and affordable by expanding the range of procedures that can be performed robotically. CMR Surgical was formerly known as Cambridge Medical Robotics. It was founded in 2014 and is based in Cambridge, United Kingdom.
Quantum Surgical is a medical device company that focuses on healthcare innovation, particularly in the domain of medical robotics. The company's main offering is a robotic-assisted technology, which is designed to plan, target, deliver, and confirm tumor ablation, thereby enabling more patients to benefit from better-targeted and less invasive treatments. Quantum Surgical primarily serves the healthcare industry, with a specific focus on interventional oncology. It was founded in 2017 and is based in Montpellier, France.
Activ Surgical is a digital surgery company that focuses on enhanced real-time visualization capabilities for surgeons. The company develops and strengthens software combining advanced augmented reality (AR), artificial intelligence (AI), and machine learning (ML) technology. Its products include ActivSight, ActivEdge, ActivPerfusion, and ActivICG. The company was founded in 2017 and is based in Boston, Massachusetts.
Intuitive Surgical develops, manufactures and markets robotic surgical systems under the da Vinci Surgical brand.
Theator develops surgical intelligence in healthcare. The company offers a platform that uses advanced artificial intelligence (AI) and computer vision technology to capture, analyze, and extract valuable surgical data, aiming to provide meaningful insights and best practices throughout a patient's surgical journey. It primarily serves hospitals and surgeons. It was founded in 2018 and is based in Palo Alto, California.
Bionaut Labs operates as a precision biotechnology company. It designs and manufactures intra- tissue navigation using Bionaut nano, microrobots operating inside the body. It offers remote-controlled micro-robots revolutionizing the treatment of central nervous system (CNS) disorders targeting deep brain structures. Its devices cater to therapeutic, microsurgical, diagnostic, sensing, monitoring, and stimulatory issues. The company was founded in 2016 and is based in Los Angeles, California.
Loading...